[S5] Symposium 5"Genetic Diseases”

[S5-1] Efficacy and Safety of a Novel Therapeutic Agent (Gene Therapy drug: ARU-2801) for the Treatment of Hypophosphatasia

^○Tae Matsumoto^1,2, Dongwei Zhao², Noriko Miyake³, Sonoko Narisawa⁴, Jos? Luis Mill?n⁴, Koichi Miyake² (1.Department of Pediatrics, Nippon Medical School, Tokyo, 2.Department of Gene Therapy, Nippon Medical School, Tokyo, 3.Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, 4.Sanford Children’s Health Research Center, Sanford-Burnham-Prebys Medical Discovery Institute, La Jolla, CA.)

Keywords:Hypophosphatasia gene therapy

 
 
 
Concurrent researcher, Department of Gene Therapy 2021-current 
Pediatrician, Nippon Medical School Tamanagayama hospital, Department of Pediatrics 2018-current 
Tokyo Yamate Medical Center, Department of Pediatrics 2015-2017 
Shizuoka Medical Center, Department of Pediatrics 2001-2003 
 
Senior Residency
2004      Kanagawa Children’s Medical Center, Emergency and intensive care department
 
Pediatrics Trainee
Japanese Red Cross Tokyo Katsushika Perinatal Center, NICU 2001
Nippon Medical School, Department of Pediatrics 1999-2001